[HTML][HTML] Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus …
DO Persky, D Dornan, BH Goldman, RM Braziel… - …, 2012 - ncbi.nlm.nih.gov
Haematologica, 2012•ncbi.nlm.nih.gov
Background Fc gamma receptor polymorphisms were linked to outcome in follicular
lymphoma patients treated with single-agent rituximab, an anti-CD20 monoclonal antibody.
In particular, 158F/F genotype of Fc gamma receptor 3A and 131R/R genotype of Fc gamma
receptor 2A correlated with worse outcome compared to high-affinity 158V/V and 131H/H,
respectively. We examined this association in the context of anti-CD20 monoclonal antibody
combined with chemotherapy, as compared to chemotherapy alone, in follicular lymphoma …
lymphoma patients treated with single-agent rituximab, an anti-CD20 monoclonal antibody.
In particular, 158F/F genotype of Fc gamma receptor 3A and 131R/R genotype of Fc gamma
receptor 2A correlated with worse outcome compared to high-affinity 158V/V and 131H/H,
respectively. We examined this association in the context of anti-CD20 monoclonal antibody
combined with chemotherapy, as compared to chemotherapy alone, in follicular lymphoma …
Abstract
Background
Fc gamma receptor polymorphisms were linked to outcome in follicular lymphoma patients treated with single-agent rituximab, an anti-CD20 monoclonal antibody. In particular, 158F/F genotype of Fc gamma receptor 3A and 131R/R genotype of Fc gamma receptor 2A correlated with worse outcome compared to high-affinity 158V/V and 131H/H, respectively. We examined this association in the context of anti-CD20 monoclonal antibody combined with chemotherapy, as compared to chemotherapy alone, in follicular lymphoma patients treated on SWOG clinical trials.
ncbi.nlm.nih.gov